32632-24-9

Basic information

• Product Name: 4-farnesyloxybenzoic acid
• Synonyms: 4-farnesyloxybenzoic acid
• CAS NO: 32632-24-9
• Molecular Weight: 342.478
• Mol File: 32632-24-9.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 4-farnesyloxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-farnesyloxybenzoic acid(32632-24-9)
• EPA Substance Registry System: 4-farnesyloxybenzoic acid(32632-24-9)

Safety Data

• Hazardous Substances Data: 32632-24-9(Hazardous Substances Data)

Upstream product

• 6784-45-8 1-chloro-3,7,11-trimethyldodeca-2,6,10-triene 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 24163-94-8 (2E,6Z)-1-bromo-3,7,11-trimethyl-2,6,10-dodecatriene 

Downstream Products

• 183583-82-6 N-(1,2-diethyl-4-pyrazolidinyl)-4-(trans, trans-farnesyloxy) benzamide 
• 34596-41-3 p-[(3,7,11-trimethyl-dodeca-2,6,10-trienyl)oxy]benzoic acid propargyl ester 

Relevant articles and documents

2-Aryl benzazole derived new class of anti-tubercular compounds: Endowed to eradicate mycobacterium tuberculosis in replicating and non-replicating forms

The high mortality rate and the increasing prevalence of Mtb resistance are the major concerns for the Tuberculosis (TB) treatment in this century. To counteract the prevalence of Mtb resistance, we have synthesized 2-aryl benzazole based dual targeted molecules. Compound 9m and 9n were found to be equally active against replicating and non-replicating form of Mtb (MIC(MABA) 1.98 and 1.66 μg/ml; MIC(LORA) 2.06 and 1.59 μg/ml respectively). They arrested the cell division (replicating Mtb) by inhibiting the GTPase activity of FtsZ with IC50 values 45 and 64 μM respectively. They were also capable of kill Mtb in non-replicating form by inhibiting the biosynthesis of menaquinone which was substantiated by the MenG inhibition (IC50 = 11.62 and 7.49 μM respectively) followed by the Vit-K2 rescue study and ATP production assay.

Alkylenediamine derivative, anti-ulcer drug, and antibacterial drug

An alkylenediamine derivative or a salt thereof expressed by the following formula 1: STR1 wherein each of R1 and R2 represents a lower alkyl group, and W represents a group expressed by any of the following formulas 2 and 3; STR2 wh

Pyrazolidine derivative radical scavenger brain-infarction depressant and brain-edema depressant

A pyrazolidine derivative or a salt thereof in accordance with the present invention is expressed by the following formula 1: STR1 wherein A represents a group expressed by --CH2 --, --CO--, --CS--, --CH2 CO--, or --CH=CH--CO--; B represents a group expressed by --O-- or --NH--; n is an integer of 1 or 2; R represents an alkenyl group; and R1 and R2 represent a lower alkyl or benzyl group. The pyrazolidine derivative above mentioned, as a radical scavenger, has antioxidant effect and lipid peroxidation inhibitory activity so as to be available for inhibiting brain infarction or brain edema.